Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PI-2620 PET Imaging in Progressive Supranuclear Palsy
NCT05187546Phase 1Completed
- Sponsor
- Life Molecular Imaging
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-PI-2620 in progressive supranuclear palsy (PSP) (2 arms), sponsored by Life Molecular Imaging. Primary endpoints: Test-retest variability of the [18F]PI-2620 binding parameters up to 74 days and Number of adverse events up to 74 days. Started Mar 2022; status: completed.
02
Drugs
18F-PI-2620
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT05187546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187546.